Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease
Authors:
- Paula RavenscroftPRPaula Ravenscroft
- Erwan BezardEBErwan Bezard
- Alan R. CrossmanACAlan R. Crossman
- Jonathan M. BrotchieJBJonathan M. Brotchie
- Anne MichelAMAnne Michel
- Renee GriméeRGRenee Grimée
- Henrik KlitgaardHKHenrik Klitgaard
- 1 July 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 310 (1) , 386-394
Abstract
Levetiracetam (LEV) (Keppra; UCB Pharma, Brussels, Belgium) has recently been reported to have antidyskinetic activity against levodopa (l-DOPA)-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset and macaque models of Parkinson9s disease. Amantadine is frequently used as adjunctive therapy for l-DOPA-induced dyskinesia, but adverse effects limit its clinical utility. The current study was designed to investigate whether LEV can potentiate the antidyskinetic action of amantadine. The antiparkinsonian and antidyskinetic effects of LEV (13 and 60 mg/kg) and amantadine (0.01, 0.03, 0.1, and 0.3 mg/kg), administered alone and in combination, were assessed in the MPTP-lesioned marmoset model of l-DOPA-induced dyskinesia (n = 12). LEV (60 mg/kg) and amantadine (0.3 mg/kg) administered alone significantly reduced l-DOPA-induced dyskinesia without compromising the antiparkinsonian action of l-DOPA. Lower doses were without any significant effects. The combination of LEV (60 mg/kg) and amantadine (0.01, 0.03, 0.1, and 0.3 mg/kg) significantly decreased dyskinesia severity, without compromising the antiparkinsonian action of l-DOPA, more efficaciously than LEV or amantadine monotherapy. These results support the concept that normalization of different pathophysiological mechanisms (i.e., altered synchronization between neurons and enhanced N-methyl-d-aspartate transmission) has a greater efficacy. Combined LEV/amantadine therapy might be useful as an adjunct to l-DOPA to treat dyskinetic side effects and to expand the population of Parkinson9s disease patients who benefit from treatment with amantadine alone.Keywords
This publication has 37 references indexed in Scilit:
- Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaqueEuropean Journal of Pharmacology, 2004
- Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor functionNature Medicine, 2003
- From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor controlProgress in Neurobiology, 2002
- Pathophysiology of levodopa-induced dyskinesia: Potential for new therapiesNature Reviews Neuroscience, 2001
- Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled studyMovement Disorders, 2001
- Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkeyBrain, 2001
- Endothelin-1 in the brain of patients with galactosialidosis: Its abnormal increase and distribution patternAnnals of Neurology, 2000
- Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeysMovement Disorders, 1998
- Amantadine in Parkinson's diseaseNeurology, 1975
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969